Maria Anna Bantounou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Anna Bantounou has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Demetrios George Vavvas
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA
6 shared publications - Konstantinos G. Baroutis
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Maria Emfietzoglou
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA
4 shared publications - Joan W. Miller
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA
3 shared publications - Josip Plascevic
Massachusetts General Hospital, Harvard Medical School, Massachusetts, United States
3 shared publications Josip Plascevic
School of Medicine, University of Aberdeen , Aberdeen
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0357009
Shotgun metagenomic profiling of the fecal microbiome in Lamp2 knockout mice reveals limited genotype-associated differences under standard housing
Background: Lysosomal pathways influence host–microbe interactions, but the microbiome consequences of lysosomal dysfunction remain incompletely defined. LAMP2 is required for autophagosome–lysosome fusion, and pathogenic variants in LAMP2 cause Danon disease. Whether Lamp2 loss alters the gut microbiome in vivo has not been systematically evaluated using methods that profile both taxonomic composition and microbial functional potential, such as shotgun metagenomics. Methods: We performed shotgun metagenomic sequencing on 50 fecal samples from male Lamp2 knockout ( Lamp2 KO) mice and wild-type (WT) littermates sampled at 3, 6, 9, and 12 months under single-genotype cages or mixed-genotype cohousing. Two low-depth libraries (5 classified genus-level reads) were excluded from primary inference (primary set: n = 48). We analyzed genus-level alpha diversity, beta diversity, and differential abundance using compositional, cage-aware mixed-effects models and cage-blocked permutation testing. We analyzed functional pathway profiles using copies-per-million abundances with centered-log-ratio transformation and mixed-effects modeling. We controlled multiple testing using the Benjamini–Hochberg false discovery rate. Results: In the primary set (48 samples from 27 cages), Lamp2 KO and WT mice showed similar genus-level alpha diversity and overall community composition (PERMANOVA using Aitchison and Bray–Curtis distances). Primary mixed-effects models detected no genera with differential abundance after false discovery rate correction. Taxonomic profiles were broadly similar between genotypes and were dominated by Bacteroidota and Bacillota. Exploratory within-cage (paired) analyses identified consistent directional differences in a small set of genera, but these signals were not supported by the primary mixed-effects models. Functional pathway profiles were similar between genotypes; one pathway (dTDP-β-L-rhamnose biosynthesis) showed an exploratory association (FDR q < 0.10) within the 50 most abundant pathways. Conclusions: In this controlled mouse cohort, we did not detect robust, cage-independent shifts in fecal microbiome composition or inferred functional pathway profiles associated with Lamp2 deficiency under standard SPF husbandry and chow; given the sample size, smaller or compartment-specific effects cannot be excluded.
- 18 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0357009
Open AccessShotgun metagenomic profiling of the fecal microbiome in Lamp2 knockout mice reveals limited genotype-associated differences under standard housing
Background: Lysosomal pathways influence host–microbe interactions, but the microbiome consequences of lysosomal dysfunction remain incompletely defined. LAMP2 is required for autophagosome–lysosome fusion, and pathogenic variants in LAMP2 cause Danon disease. Whether Lamp2 loss alters the gut microbiome in vivo has not been systematically evaluated using methods that profile both taxonomic composition and microbial functional potential, such as shotgun metagenomics. Methods: We performed shotgun metagenomic sequencing on 50 fecal samples from male Lamp2 knockout ( Lamp2 KO) mice and wild-type (WT) littermates sampled at 3, 6, 9, and 12 months under single-genotype cages or mixed-genotype cohousing. Two low-depth libraries (5 classified genus-level reads) were excluded from primary inference (primary set: n = 48). We analyzed genus-level alpha diversity, beta diversity, and differential abundance using compositional, cage-aware mixed-effects models and cage-blocked permutation testing. We analyzed functional pathway profiles using copies-per-million abundances with centered-log-ratio transformation and mixed-effects modeling. We controlled multiple testing using the Benjamini–Hochberg false discovery rate. Results: In the primary set (48 samples from 27 cages), Lamp2 KO and WT mice showed similar genus-level alpha diversity and overall community composition (PERMANOVA using Aitchison and Bray–Curtis distances). Primary mixed-effects models detected no genera with differential abundance after false discovery rate correction. Taxonomic profiles were broadly similar between genotypes and were dominated by Bacteroidota and Bacillota. Exploratory within-cage (paired) analyses identified consistent directional differences in a small set of genera, but these signals were not supported by the primary mixed-effects models. Functional pathway profiles were similar between genotypes; one pathway (dTDP-β-L-rhamnose biosynthesis) showed an exploratory association (FDR q < 0.10) within the 50 most abundant pathways. Conclusions: In this controlled mouse cohort, we did not detect robust, cage-independent shifts in fecal microbiome composition or inferred functional pathway profiles associated with Lamp2 deficiency under standard SPF husbandry and chow; given the sample size, smaller or compartment-specific effects cannot be excluded.
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 11 (3) , e002935
Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study
Objective: Proton-pump inhibitors (PPIs) may disrupt lysosomal acidification, a pathway implicated in age-related macular degeneration (AMD) pathogenesis. We evaluated whether sustained PPI exposure increased the risk of incident AMD in older adults aged ≥60 years. Methods and analysis: This retrospective observational cohort study included adults aged ≥60 years with sustained PPI exposure, matched 1:1 to unexposed controls on demographics, overall health, healthcare utilisation, cardiometabolic factors. Participants were identified from electronic health records. Sustained PPI exposure was defined as ≥2 years of cumulative use within 3 years of the first prescription. Fine-Gray models treating death as a competing event estimated subdistribution hazard ratios (sHRs) for AMD within 10 years; cause-specific Cox models provided complementary HRs. Analyses included histamine H2-receptor antagonists (H2-antagonists) as a negative exposure control and active comparator. Results: Incident AMD occurred in 814/49 796 PPI exposed participants (1.64%) and 668/49 796 controls (1.34%) (overall sHR=1.24, 95% CI 1.12 to 1.38; p<0.001; HR=1.25, 95% CI 1.13 to 1.38, p<0.001). Proportional sHRs were non-constant; sHRs were 1.09 (95% CI 0.91 to 1.29) before 2.5 years and 1.33 (95% CI 1.17 to 1.51) thereafter. For non-exudative AMD, 640 PPI exposed (1.29%) and 510 unexposed (1.02%) participants developed disease (overall sHR=1.28, 95% CI 1.14 to 1.44; p<0.001, HR=1.29, 95% CI 1.14 to 1.44, p<0.001). Among those with non-exudative AMD, 190/2503 PPI-exposed participants (7.59%) and 179/2503 controls (7.15%) progressed to exudative AMD (sHR and HR=1.03, 95% CI 0.84 to 1.26; p=0.802 and p=0.801, respectively). No association was observed between H2-antagonists and AMD (sHR=1.02, 95% CI 0.88 to 1.19; p=0.784; HR=1.03, 95% CI 0.88 to 1.20, p=0.729). Results were consistent in the active-comparator analysis (reciprocal overall sHR=1.24, 95% CI 1.04 to 1.48; p=0.016; HR=1.25, 95% CI 1.05 to 1.49, p=0.012). Conclusion: Sustained PPI exposure was associated with a modestly higher AMD risk, whereas no association was observed with H2-antagonists. The consistency of the active-comparator findings supports the potential specificity of this association and warrants further investigation to determine its clinical implications.
- 1 July 2026
- Published by BMJ in BMJ Open Ophthalmology
- Vol. 11 (3) , e002935
Open AccessSustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study
Objective: Proton-pump inhibitors (PPIs) may disrupt lysosomal acidification, a pathway implicated in age-related macular degeneration (AMD) pathogenesis. We evaluated whether sustained PPI exposure increased the risk of incident AMD in older adults aged ≥60 years. Methods and analysis: This retrospective observational cohort study included adults aged ≥60 years with sustained PPI exposure, matched 1:1 to unexposed controls on demographics, overall health, healthcare utilisation, cardiometabolic factors. Participants were identified from electronic health records. Sustained PPI exposure was defined as ≥2 years of cumulative use within 3 years of the first prescription. Fine-Gray models treating death as a competing event estimated subdistribution hazard ratios (sHRs) for AMD within 10 years; cause-specific Cox models provided complementary HRs. Analyses included histamine H2-receptor antagonists (H2-antagonists) as a negative exposure control and active comparator. Results: Incident AMD occurred in 814/49 796 PPI exposed participants (1.64%) and 668/49 796 controls (1.34%) (overall sHR=1.24, 95% CI 1.12 to 1.38; p<0.001; HR=1.25, 95% CI 1.13 to 1.38, p<0.001). Proportional sHRs were non-constant; sHRs were 1.09 (95% CI 0.91 to 1.29) before 2.5 years and 1.33 (95% CI 1.17 to 1.51) thereafter. For non-exudative AMD, 640 PPI exposed (1.29%) and 510 unexposed (1.02%) participants developed disease (overall sHR=1.28, 95% CI 1.14 to 1.44; p<0.001, HR=1.29, 95% CI 1.14 to 1.44, p<0.001). Among those with non-exudative AMD, 190/2503 PPI-exposed participants (7.59%) and 179/2503 controls (7.15%) progressed to exudative AMD (sHR and HR=1.03, 95% CI 0.84 to 1.26; p=0.802 and p=0.801, respectively). No association was observed between H2-antagonists and AMD (sHR=1.02, 95% CI 0.88 to 1.19; p=0.784; HR=1.03, 95% CI 0.88 to 1.20, p=0.729). Results were consistent in the active-comparator analysis (reciprocal overall sHR=1.24, 95% CI 1.04 to 1.48; p=0.016; HR=1.25, 95% CI 1.05 to 1.49, p=0.012). Conclusion: Sustained PPI exposure was associated with a modestly higher AMD risk, whereas no association was observed with H2-antagonists. The consistency of the active-comparator findings supports the potential specificity of this association and warrants further investigation to determine its clinical implications.
- 29 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (11) , 1083-1091
Systemic Statin Use and Reduced Risk of Repeat Retinal Detachment Repair
- 29 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (11) , 1083-1091
Systemic Statin Use and Reduced Risk of Repeat Retinal Detachment Repair
- 22 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (13) , 2075-2082
Recent vaccination exposure and central serous chorioretinopathy
Central serous chorioretinopathy (CSCR) is characterised by choroidal hyperpermeability and potential dysregulation of inflammatory cytokines. Because vaccination transiently activates cytokine pathways, we assessed whether vaccination is associated with incident CSCR. We performed a case-control study in the Mass General Brigham database among adults 18-60 years. CSCR cases were matched 4:1 to controls by demographics, systemic conditions relevant to vaccination likelihood or infection susceptibility, CSCR risk factors, healthcare utilisation and index month/year. Vaccination within 90 days before index was evaluated overall, by vaccine category, and by time window (1-10, 11-45, and 46-90 days before index); odds ratios (ORs) were estimated. Among 3 205 CSCR cases, 66 (2.1%) had recorded vaccination within 90 days before index compared with 232 (1.8%) of 12 753 controls (OR 1.14, 95% CI 0.86-1.50; P = 0.37). No associations were observed for influenza (OR 1.09, 95% CI 0.74-1.60; P = 0.67), COVID-19 (OR 1.00, 95% CI 0.37-2.66; P = 0.99), or tetanus-containing vaccines (OR 1.20, 95% CI 0.73-1.95; P = 0.48). Vaccination within 1-10 days before index was associated with higher odds of CSCR (OR 2.00, 95% CI 1.02-3.89; P = 0.043). Case-crossover analysis showed similar temporal clustering (OR 3.25, 95% CI 1.06-9.97; P = 0.039). Vaccination within 1-10 days before index was associated with higher odds of CSCR, although vaccination within 90 days was not. These findings do not support changes to vaccination practice for patients at risk of CSCR, but highlight the need for larger studies with complete vaccine capture to evaluate CSCR risk during the acute post-vaccination period.
- 22 June 2026
- Published by Springer Nature in Eye
- Vol. 40 (13) , 2075-2082
Recent vaccination exposure and central serous chorioretinopathy
Central serous chorioretinopathy (CSCR) is characterised by choroidal hyperpermeability and potential dysregulation of inflammatory cytokines. Because vaccination transiently activates cytokine pathways, we assessed whether vaccination is associated with incident CSCR. We performed a case-control study in the Mass General Brigham database among adults 18-60 years. CSCR cases were matched 4:1 to controls by demographics, systemic conditions relevant to vaccination likelihood or infection susceptibility, CSCR risk factors, healthcare utilisation and index month/year. Vaccination within 90 days before index was evaluated overall, by vaccine category, and by time window (1-10, 11-45, and 46-90 days before index); odds ratios (ORs) were estimated. Among 3 205 CSCR cases, 66 (2.1%) had recorded vaccination within 90 days before index compared with 232 (1.8%) of 12 753 controls (OR 1.14, 95% CI 0.86-1.50; P = 0.37). No associations were observed for influenza (OR 1.09, 95% CI 0.74-1.60; P = 0.67), COVID-19 (OR 1.00, 95% CI 0.37-2.66; P = 0.99), or tetanus-containing vaccines (OR 1.20, 95% CI 0.73-1.95; P = 0.48). Vaccination within 1-10 days before index was associated with higher odds of CSCR (OR 2.00, 95% CI 1.02-3.89; P = 0.043). Case-crossover analysis showed similar temporal clustering (OR 3.25, 95% CI 1.06-9.97; P = 0.039). Vaccination within 1-10 days before index was associated with higher odds of CSCR, although vaccination within 90 days was not. These findings do not support changes to vaccination practice for patients at risk of CSCR, but highlight the need for larger studies with complete vaccine capture to evaluate CSCR risk during the acute post-vaccination period.
- 13 May 2026
- Published by BMJ in British Journal of Ophthalmology
Epiretinal membrane formation risk after prophylactic laser photocoagulation for lattice degeneration: a retrospective cohort study
Prophylactic treatment of lattice degeneration with laser photocoagulation remains controversial. We evaluated whether prophylactic laser for lattice degeneration increases epiretinal membrane (ERM) risk. In a retrospective cohort (2005–2025), patients receiving laser within 90 days of lattice diagnosis were classified as exposed; untreated patients served as controls and were matched 3:1. ERM within 10 years was analysed using Fine–Gray competing-risk models (death as competing event). ERM occurred in 38/321 (11.8%) laser-treated versus 53/944 (5.6%) untreated patients (sHR=2.50, 95% CI 1.65 to 3.79; p<0.001). Prophylactic laser was associated with higher ERM risk, warranting careful consideration of its risk–benefit profile.
- 13 May 2026
- Published by BMJ in British Journal of Ophthalmology
Epiretinal membrane formation risk after prophylactic laser photocoagulation for lattice degeneration: a retrospective cohort study
Prophylactic treatment of lattice degeneration with laser photocoagulation remains controversial. We evaluated whether prophylactic laser for lattice degeneration increases epiretinal membrane (ERM) risk. In a retrospective cohort (2005–2025), patients receiving laser within 90 days of lattice diagnosis were classified as exposed; untreated patients served as controls and were matched 3:1. ERM within 10 years was analysed using Fine–Gray competing-risk models (death as competing event). ERM occurred in 38/321 (11.8%) laser-treated versus 53/944 (5.6%) untreated patients (sHR=2.50, 95% CI 1.65 to 3.79; p<0.001). Prophylactic laser was associated with higher ERM risk, warranting careful consideration of its risk–benefit profile.
- 10 October 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (3) , 283-293
Litigation Involving Intravitreal Injections in Ophthalmology
- 10 October 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (3) , 283-293
Litigation Involving Intravitreal Injections in Ophthalmology
- Open Access
- 10 September 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (2) , 968-979
Meta-Analysis of Sotagliflozin, a Dual Sodium-Glucose-Cotransporter 1/2 Inhibitor, for Heart Failure in Type 2 Diabetes
Sodium-glucose co-transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from inception until 2 June 2023. Randomized controlled trials evaluating sotagliflozin in type 2 diabetes participants and reporting HF events were selected. Major adverse cardiovascular events (MACE) and systolic blood pressure were evaluated. The Cochrane risk of bias tool (RoB 2.0) was used. Pooled mean difference (MD), relative risk (RR), 95% confidence intervals and the number needed to treat (NNT) were estimated (PROSPERO: CRD42023432732). We selected nine studies (n = 15 320 participants: n = 8040 intervention and n = 7280 control). The median follow-up was 13.4 months (Q1 = 13, Q3 = 21). One study recruited participants with HF at baseline. After a follow-up of >52 weeks, sotagliflozin significantly reduced the risk of HF [n = 8 studies; RR = 0.66 (0.64, 0.69)], stroke [n = 6 studies; RR = 0.75 (0.58, 0.97)] and MACE [n = 8 studies; RR = 0.73 (0.66, 0.81)]. The NNT was 20 and 26 for HF and MACE, respectively. Sotagliflozin lowered systolic blood pressure [n = 7; MD = −2.38 mmHg (−2.79, −1.97)]. No dose-dependent effect was identified for HF [200 mg: RR = 0.38 (0.16, 0.89), 400 mg: RR = 0.57 (0.39, 0.85), P-value = 0.22]. The high risk of bias was a limitation of this review. Sotagliflozin reduced HF and cardiovascular events in type 2 diabetes participants. Research exploring its effects in HF and comparisons with SGLT2 inhibitors is warranted to determine if dual SGLT inhibition surpasses selective inhibition.
- 10 September 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (2) , 968-979
Open AccessMeta-Analysis of Sotagliflozin, a Dual Sodium-Glucose-Cotransporter 1/2 Inhibitor, for Heart Failure in Type 2 Diabetes
Sodium-glucose co-transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from inception until 2 June 2023. Randomized controlled trials evaluating sotagliflozin in type 2 diabetes participants and reporting HF events were selected. Major adverse cardiovascular events (MACE) and systolic blood pressure were evaluated. The Cochrane risk of bias tool (RoB 2.0) was used. Pooled mean difference (MD), relative risk (RR), 95% confidence intervals and the number needed to treat (NNT) were estimated (PROSPERO: CRD42023432732). We selected nine studies (n = 15 320 participants: n = 8040 intervention and n = 7280 control). The median follow-up was 13.4 months (Q1 = 13, Q3 = 21). One study recruited participants with HF at baseline. After a follow-up of >52 weeks, sotagliflozin significantly reduced the risk of HF [n = 8 studies; RR = 0.66 (0.64, 0.69)], stroke [n = 6 studies; RR = 0.75 (0.58, 0.97)] and MACE [n = 8 studies; RR = 0.73 (0.66, 0.81)]. The NNT was 20 and 26 for HF and MACE, respectively. Sotagliflozin lowered systolic blood pressure [n = 7; MD = −2.38 mmHg (−2.79, −1.97)]. No dose-dependent effect was identified for HF [200 mg: RR = 0.38 (0.16, 0.89), 400 mg: RR = 0.57 (0.39, 0.85), P-value = 0.22]. The high risk of bias was a limitation of this review. Sotagliflozin reduced HF and cardiovascular events in type 2 diabetes participants. Research exploring its effects in HF and comparisons with SGLT2 inhibitors is warranted to determine if dual SGLT inhibition surpasses selective inhibition.
- Open Access
- 14 August 2024
- Published by Elsevier in Brain Disorders
- Vol. 15
The association between type 2 diabetes mellitus and Parkinson's disease; a systematic review and meta-analysis
- 14 August 2024
- Published by Elsevier in Brain Disorders
- Vol. 15
Open AccessThe association between type 2 diabetes mellitus and Parkinson's disease; a systematic review and meta-analysis
- Open Access
- 29 November 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 710-720
Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium‐glucose co‐transporter‐1 and ‐2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the risk of further renal events, with an emphasis on those with previous renal impairment. Methods: Embase, Medline, CENTRAL and Scopus were searched from their inception until 24 April 2023 for randomized controlled trials that reported estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE). The Cochrane risk of bias 2 tool was used. Mean difference, relative risk (RR) and 95% confidence intervals were estimated (PROSPERO: CRD42023425583). Results: Fourteen studies were included in this review ( n = 17 574 participants; intervention n = 9312, control n = 8262). The median follow‐up was 24.5 (Q1 = 15.25, Q3 = 28) months. Four studies recruited participants with renal impairment; baseline eGFR ranged from 23.8 to 50.5 mL/min/1.73m 2 . The change in eGFR for studies ( n = 6) with a follow‐up of 52 weeks or longer was −1.23 (−1.45, −1.01) mL/min/1.73m 2 . Sotagliflozin did not significantly alter urinary albumin excretion. No change was observed in the risk of CRE ( n = 6 studies; RR = 0.82 [0.61, 1.12]), including in participants with renal impairment. High risk of bias was a limitation of this review. Conclusions: Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre‐existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.
- 29 November 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 710-720
Open AccessEffect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium‐glucose co‐transporter‐1 and ‐2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the risk of further renal events, with an emphasis on those with previous renal impairment. Methods: Embase, Medline, CENTRAL and Scopus were searched from their inception until 24 April 2023 for randomized controlled trials that reported estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE). The Cochrane risk of bias 2 tool was used. Mean difference, relative risk (RR) and 95% confidence intervals were estimated (PROSPERO: CRD42023425583). Results: Fourteen studies were included in this review ( n = 17 574 participants; intervention n = 9312, control n = 8262). The median follow‐up was 24.5 (Q1 = 15.25, Q3 = 28) months. Four studies recruited participants with renal impairment; baseline eGFR ranged from 23.8 to 50.5 mL/min/1.73m 2 . The change in eGFR for studies ( n = 6) with a follow‐up of 52 weeks or longer was −1.23 (−1.45, −1.01) mL/min/1.73m 2 . Sotagliflozin did not significantly alter urinary albumin excretion. No change was observed in the risk of CRE ( n = 6 studies; RR = 0.82 [0.61, 1.12]), including in participants with renal impairment. High risk of bias was a limitation of this review. Conclusions: Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre‐existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.